June 18, 2019 11:01 AM EDT

Unity's early longevity data look 'encouraging'; Adaptive Biotechnologies looks to raise $200M in IPO

ENDPOINTS

→ Bob Nelsen-backed longevity startup Unity $UBX on Tuesday unveiled the first ever in-human data on its drug, UBX0101, which is designed to delay …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Unity's early longevity data look 'encouraging'; Adaptive Biotechnologies looks to raise $200M in IPO

ENDPOINTS

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Sofinnova outlines $550M fund after IPOs and M&A deals

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Uni­ty's ear­ly longevi­ty da­ta look 'en­cour­ag­ing'; Adap­tive Biotech­nolo­gies looks to raise $200M in IPO

ENDPOINTS

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Unity's early longevity data look 'encouraging'; Adaptive Biotechnologies looks to raise $200M in IPO

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Sofinnova outlines $550M fund after IPOs and M&A deals

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients